Current research suggests that the flu may predispose to secondary bacterial infections, which account for a significant proportion of mortality during flu pandemics. The related report by Lee, et al., "A mouse model of lethal synergism between influenza virus and Haemophilus influenzae," appears in the February 2010 issue of the American Journal of Pathology.
Influenza affects between 3 million and 5 million people annually, causing up to 500,000 deaths worldwide. While most people will recover in one to two weeks, others will develop life-threatening conditions such as pneumonia or bronchitis. High-risk groups for seasonal influenza include the very young and old, people with compromised immune systems, and pregnant women. However, during influenza pandemics, mortality may be significant in previously healthy young adults.
A common complication of flu infection is a secondary "super-infection" by bacteria, which greatly increases the morbidity and mortality of the disease. The most common bacterial agents found following flu pandemics have been Streptococcus pneumoniae, Haemophilus influenzae, Group A Streptococcus, and Staphylococcus aureus. Furthermore, reports of infection with antibiotic-resistant strains have been increasing in recent years.
To explore the mechanisms governing the increased pathogenesis of flu upon super-infection, a group led by Dr. Sally R. Sarawar of the Torrey Pines Institute for Molecular Studies in San Diego confirmed that otherwise nonlethal influenza and H. influenzae infections cause high mortality rates in mice when flu infection precedes H. influenzae infection. Their data confirm a restricted time period for this heightened susceptibility and highlight that excessive bacterial, and not viral, growth is associated with increased lethality. The fact that this increased mortality was observed in both immune-compromised and immune-competent mice suggests that even normal healthy people are at increased risk for complications following bacterial super-infection.
Lee, et al. suggest that the "lethal synergy between influenza virus and the bacterial respiratory pathogen, H. influenzae, is mediated by innate immunity. They observed that severe damage to the airways was an early event in the co-infected mice, eventually leading to death. This underscores the need for early antiviral and antibiotic treatment to combat severe disease in human patients and highlights the importance of vaccination and effective hygiene measures to prevent secondary bacterial infections during influenza infection. This new model will be useful for further investigating the mechanisms underlying severe disease caused by the interaction between influenza virus and bacteria, which may have resulted in numerous deaths during influenza pandemics and continues to constitute a significant clinical problem in susceptible individuals." Currently ongoing studies suggest that this model may also be useful for identifying target molecules for the development of novel therapeutic agents and strategies.
This work was supported by the National Institutes of Health Grant AI59429 and by a grant from the Infectious Disease Science Center.
Reference: Lee LN, Dias P, Han D, Yoon S, Shea A, Zakharov V, Parham D, Sarawar SR: A mouse model of lethal synergism between influenza virus and Haemophilus influenzae. Am J Pathol 176: 800-811.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.